Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Statin intolerance presents a considerable challenge in managing patients at risk for cardiovascular diseases, as it limits patients' access to standard lipid-lowering therapies.
Objective: This study aims to compare the efficacy and safety of various nonstatin lipid-lowering therapies in patients who are intolerant to statins.
Methods: We searched PubMed, Embase, CENTRAL, and EBSCO open dissertations through September 2023 for randomized controlled trials in statin-intolerant patients comparing nonstatin lipid-lowering agents. The primary outcome was low-density lipoprotein cholesterol (LDL-C). A random-effects model estimated comparative effects using mean differences (MDs) for LDL-C reduction and relative risks (RRs) for safety outcomes, specifically trial withdrawal due to adverse events. Results were reported with 95% CIs, and therapies ranked using the surface under the cumulative ranking curve (SUCRA). Evidence certainty was assessed with the Confidence in Network Meta-Analysis (CINeMA) platform.
Results: Of 1533 articles, 6 studies (1326 patients) met inclusion criteria. Evolocumab combined with ezetimibe achieved the greatest LDL-C reduction (MD: 48.98%; 95% CI: 59.19, -38.77) vs ezetimibe alone, with moderate evidence certainty. Evolocumab, alirocumab, and the combination of bempedoic acid and ezetimibe, also showed significant reductions in LDL-C compared to ezetimibe monotherapy, though the magnitude of their effects was smaller than that of the evolocumab and ezetimibe combination. The SUCRA of evolocumab and ezetimibe (99.7%) aligns with its highest comparative efficacy. No significant differences in safety outcomes were observed across treatments.
Conclusion: Evolocumab combined with ezetimibe is the most effective regimen for LDL-C reduction, with a safety profile comparable to other treatments, making it a viable alternative for patients with statin intolerance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2025.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
Lancet
August 2025
Department of Anesthesia, St Michael's Hospital-Unity Health Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada; Department of Physiology, Univ
Background: Saphenous vein graft (SVG) failure remains a substantial challenge after coronary artery bypass graft (CABG). LDL cholesterol (LDL-C) is a causal risk factor for atherosclerosis, but its role in SVG failure is not well established. We evaluated whether early initiation of intensive LDL-C lowering with evolocumab could reduce SVG failure.
View Article and Find Full Text PDFBlack Cumin Seed () Confers Anti-Adipogenic Effects in 3T3-L1 Cellular Model and Lipid-Lowering Properties in Human Subjects.
Food Sci Nutr
September 2025
Department of Nutrition, Graduate School of Human Life and Ecology Osaka Metropolitan University Osaka Japan.
(black cumin seed) has traditionally been valued for its medicinal properties. This study explored its potential in addressing obesity-related conditions by assessing its anti-adipogenic and lipid-lowering effects. Black cumin seed extract showed high phenolic (35.
View Article and Find Full Text PDFSynergy analysis of cyanidin-3-O-glucoside and catechin: absorption, transport and lipid metabolism effects.
Front Nutr
August 2025
College of Food Science and Engineering, Jilin Agricultural University, Changchun, Jilin, China.
Hyperlipidemia represents a global metabolic epidemic with increasing prevalence, profoundly associated with the etiology of cardiovascular and cerebrovascular diseases. This study investigates the therapeutic potential of two widely distributed bioactive polyphenols, Cyanidin-3-O-glucoside (C3G), catechin, and their synergistic combinatorial formation (C3G-catechin) in modulating hyperlipidemia, using complementary models (Caco-2 monolayer and Caco-2/HepG2 co-culture systems) to simulate intestinal absorption dynamics and lipid metabolic regulation. Our results reveal that the intestinal absorption efficiency follows the order of catechin > C3G-catechin > C3G, primarily mediated through passive diffusion.
View Article and Find Full Text PDFElucidating the gut microbiota-driven crosstalk: mechanistic interplay of lobetyolin in coordinating cholesterol homeostasis and anti-inflammatory pathways in hyperlipidemic mice models.
Front Microbiol
August 2025
School of Pharmacy, Changzhi Medical College, Changzhi, Shanxi, China.
Background: Hyperlipidemia is a prevalent metabolic disorder closely associated with gut microbiota imbalance. In recent years, traditional Chinese medicine has demonstrated distinct advantages in the regulation of the gut microbiota and enhancement of metabolic health. This study aimed to elucidate the molecular processes by which lobetyolin modifies the gut microbiota to improve intestinal inflammation and lipid metabolism in hyperlipidemic mice.
View Article and Find Full Text PDFChoosing the optimal nonstatin lipid lowering therapies for statin-intolerant patients: A systematic review and network meta-analysis.
J Clin Lipidol
August 2025
The Research Unit of Evidence Synthesis (TRUES), Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand (Dr. Dhippayom); Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA (Dr. Dhippayom).
Background: Statin intolerance presents a considerable challenge in managing patients at risk for cardiovascular diseases, as it limits patients' access to standard lipid-lowering therapies.
Objective: This study aims to compare the efficacy and safety of various nonstatin lipid-lowering therapies in patients who are intolerant to statins.
Methods: We searched PubMed, Embase, CENTRAL, and EBSCO open dissertations through September 2023 for randomized controlled trials in statin-intolerant patients comparing nonstatin lipid-lowering agents.